Cargando…
Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors
Protein kinases have emerged as crucial targets for cancer therapy over the last decades. Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials. We previously repo...
Autores principales: | Francini, Cinzia Maria, Musumeci, Francesca, Fallacara, Anna Lucia, Botta, Lorenzo, Molinari, Alessio, Artusi, Roberto, Mennuni, Laura, Angelucci, Adriano, Schenone, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225123/ https://www.ncbi.nlm.nih.gov/pubmed/30227617 http://dx.doi.org/10.3390/molecules23092369 |
Ejemplares similares
-
Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
por: Navarra, Michele, et al.
Publicado: (2010) -
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation
por: Casini, Nadia, et al.
Publicado: (2015) -
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
por: Martellucci, Stefano, et al.
Publicado: (2020) -
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor
por: Fallacara, Anna Lucia, et al.
Publicado: (2019) -
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)